Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Global Gaucher Disease Treatment Market Insights
3.1. Gaucher Disease Treatment – Industry snapshot
3.2. Gaucher Disease Treatment – Ecosystem analysis
3.3. Gaucher Disease Treatment – Market dynamics
3.3.1. Gaucher Disease Treatment – Market Forces
3.3.1.1. Gaucher Disease Treatment Market driver analysis
3.3.1.2. Gaucher Disease Treatment Market restraint/challenges analysis
3.3.1.3. Gaucher Disease Treatment Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.5. Degree of competition
3.6. Gaucher Disease Treatment market PEST analysis, 2017
3.7. Value Chain Analysis
3.8. Gaucher Disease Treatment Market Industry trends
4. Gaucher Disease Treatment Market Size and Forecast by Disease type, 2018 - 2025
4.1. Key findings
4.2. Type I Gaucher Disease
4.3. Type II Gaucher Disease
4.4. Type III Gaucher Disease
5. Gaucher Disease Treatment Market Size and Forecast by Treatment type, 2018 - 2025
5.1. Key findings
5.2. Enzyme Replacement Therapy (ERT)
5.3. Substrate Reduction Therapy (SRT)
6. Gaucher Disease Treatment Market Size and Forecast by Regions, 2018-2025
6.1. Key findings
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.3. Europe
6.3.1. Germany
6.3.2. UK
6.3.3. France
6.4. Asia Pacific
6.4.1. Australia
6.5. Latin America
6.5.1. Brazil
6.6. Middle East & Africa
6.6.1. Israel
7. Company Profiles
7.1. Sonafi (Genzyme Corporation)
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Type Benchmarking
7.1.4. Recent Developments
7.2. Pfizer Inc.
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Type Benchmarking
7.2.4. Recent Developments
7.3. Acetelion Pharmaceutical (J&J Ltd.)
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Type Benchmarking
7.3.4. Recent Developments
7.4. Shire Human Genetics Therapies, Inc.
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Type Benchmarking
7.4.4. Recent Developments
7.5. Erad Therapeutic Inc.
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Type Benchmarking
7.5.4. Recent Developments
7.6. JCR Pharmaceuticals Co Ltd.
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Type Benchmarking
7.6.4. Recent Developments